Suguru Yamashita1, Jean-Nicolas Vauthey1, Ahmed O Kaseb2, Thomas A Aloia1, Claudius Conrad1, Manal M Hassan2, Guillaume Passot1, Kanwal P Raghav2, Mohamed A Shama3, Yun Shin Chun4. 1. Departments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1484, Houston, TX, 77030, USA. 2. Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt. 4. Departments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1484, Houston, TX, 77030, USA. yschun@mdanderson.org.
Abstract
BACKGROUND: Fibrolamellar carcinoma (FLC) and conventional hepatocellular carcinoma (HCC) share the same American Joint Committee on Cancer (AJCC) staging. The worse survival with HCC is attributed to the underlying cirrhosis.The aim of this study was to compare stage-matched prognosis after resection of FLC and non-cirrhotic HCC. METHODS: Outcomes after resection of 65 consecutive patients with FLC and 158 non-cirrhotic patients with HCC were compared. Patients were staged according to the 7th edition AJCC staging. RESULTS: The AJCC stage distributions for FLC and HCC demonstrated a predominance of stage IV disease in FLC and stage I in HCC (FLC stage I-23 %, II-15 %, III-15 %, IV-46 % vs. HCC stage I-42 %, II-32 %, III-20 %, IV-6 %, p < 0.001). Among stage IV FLC patients, 81 % had isolated nodal metastases, which did not affect overall survival (OS) or recurrence-free survival (RFS). In FLC, OS was significantly affected by the number of tumors and vascular invasion (p < 0.05). Recurrent disease developed in 56 (86 %) FLC patients and was treated with repeat surgical resection in 25 (45 %) patients. Vascular invasion was associated with recurrent FLC, with 3-year RFS rates of 9 % and 35 %, with and without vascular invasion (p = 0.034). With respect to RFS, the AJCC staging did not stratify FLC patients, compared to non-cirrhotic HCC. CONCLUSIONS: When compared to non-cirrhotic HCC, patients with FLC are not adequately stratified by AJCC staging with respect to RFS. Our results support classifying lymph node metastases in FLC as regional disease, rather than systemic disease. Important prognostic factors in FLC are the number of tumors and vascular invasion.
BACKGROUND:Fibrolamellar carcinoma (FLC) and conventional hepatocellular carcinoma (HCC) share the same American Joint Committee on Cancer (AJCC) staging. The worse survival with HCC is attributed to the underlying cirrhosis.The aim of this study was to compare stage-matched prognosis after resection of FLC and non-cirrhotic HCC. METHODS: Outcomes after resection of 65 consecutive patients with FLC and 158 non-cirrhotic patients with HCC were compared. Patients were staged according to the 7th edition AJCC staging. RESULTS: The AJCC stage distributions for FLC and HCC demonstrated a predominance of stage IV disease in FLC and stage I in HCC (FLC stage I-23 %, II-15 %, III-15 %, IV-46 % vs. HCC stage I-42 %, II-32 %, III-20 %, IV-6 %, p < 0.001). Among stage IV FLC patients, 81 % had isolated nodal metastases, which did not affect overall survival (OS) or recurrence-free survival (RFS). In FLC, OS was significantly affected by the number of tumors and vascular invasion (p < 0.05). Recurrent disease developed in 56 (86 %) FLC patients and was treated with repeat surgical resection in 25 (45 %) patients. Vascular invasion was associated with recurrent FLC, with 3-year RFS rates of 9 % and 35 %, with and without vascular invasion (p = 0.034). With respect to RFS, the AJCC staging did not stratify FLC patients, compared to non-cirrhotic HCC. CONCLUSIONS: When compared to non-cirrhotic HCC, patients with FLC are not adequately stratified by AJCC staging with respect to RFS. Our results support classifying lymph node metastases in FLC as regional disease, rather than systemic disease. Important prognostic factors in FLC are the number of tumors and vascular invasion.
Authors: Elana P Simon; Catherine A Freije; Benjamin A Farber; Gadi Lalazar; David G Darcy; Joshua N Honeyman; Rachel Chiaroni-Clarke; Brian D Dill; Henrik Molina; Umesh K Bhanot; Michael P La Quaglia; Brad R Rosenberg; Sanford M Simon Journal: Proc Natl Acad Sci U S A Date: 2015-10-21 Impact factor: 11.205
Authors: Ahmed O Kaseb; Mohamed Shama; Ibrahim Halil Sahin; Ajay Nooka; Hesham M Hassabo; Jean-Nicolas Vauthey; Thomas Aloia; James L Abbruzzese; Ishwaria M Subbiah; Filip Janku; Steven Curley; Manal M Hassan Journal: Oncology Date: 2013-09-19 Impact factor: 2.935
Authors: Helena Cornella; Clara Alsinet; Sergi Sayols; Zhongyang Zhang; Ke Hao; Laia Cabellos; Yujin Hoshida; Augusto Villanueva; Swan Thung; Stephen C Ward; Leonardo Rodriguez-Carunchio; Maria Vila-Casadesús; Sandrine Imbeaud; Anja Lachenmayer; Alberto Quaglia; David M Nagorney; Beatriz Minguez; Flair Carrilho; Lewis R Roberts; Samuel Waxman; Vincenzo Mazzaferro; Myron Schwartz; Manel Esteller; Nigel D Heaton; Jessica Zucman-Rossi; Josep M Llovet Journal: Gastroenterology Date: 2014-12-31 Impact factor: 22.682
Authors: V Maniaci; B R Davidson; K Rolles; A P Dhillon; A Hackshaw; R H Begent; T Meyer Journal: Eur J Surg Oncol Date: 2009-01-13 Impact factor: 4.424
Authors: Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon Journal: Science Date: 2014-02-28 Impact factor: 47.728
Authors: Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa Journal: Gastrointest Cancer Res Date: 2013-01
Authors: Tobias Eggert; Katherine A McGlynn; Austin Duffy; Michael P Manns; Tim F Greten; Sean F Altekruse Journal: United European Gastroenterol J Date: 2013-10 Impact factor: 4.623
Authors: William J Hammond; Gadi Lalazar; James A Saltsman; Benjamin A Farber; Enrico Danzer; Tshering C Sherpa; Charles D Banda; Jeffrey R Andolina; Sasan Karimi; Cameron W Brennan; Michael S Torbenson; Michael P La Quaglia; Sanford M Simon Journal: Pediatr Blood Cancer Date: 2017-12-29 Impact factor: 3.167
Authors: Kelly J Lafaro; Oliver S Eng; Mustafa Raoof; Philip Ituarte; Susanne G Warner; Gagandeep Singh; Yuman Fong; Laleh G Melstrom Journal: Hepatobiliary Surg Nutr Date: 2019-08 Impact factor: 7.293
Authors: Adam B Francisco; Matt Kanke; Andrew P Massa; Timothy A Dinh; Ramja Sritharan; Khashayar Vakili; Nabeel Bardeesy; Praveen Sethupathy Journal: JCI Insight Date: 2022-06-08
Authors: Gadi Lalazar; David Requena; Lavoisier Ramos-Espiritu; Denise Ng; Patrick D Bhola; Ype P de Jong; Ruisi Wang; Nicole J C Narayan; Bassem Shebl; Solomon Levin; Eleftherios Michailidis; Mohammad Kabbani; Koen O A Vercauteren; Arlene M Hurley; Benjamin A Farber; William J Hammond; James A Saltsman; Ethan M Weinberg; J Fraser Glickman; Barbara A Lyons; Jessica Ellison; Erik Schadde; Martin Hertl; Jennifer L Leiting; Mark J Truty; Rory L Smoot; Faith Tierney; Tomoaki Kato; Hans-Guido Wendel; Michael P LaQuaglia; Charles M Rice; Anthony Letai; Philip Coffino; Michael S Torbenson; Michael V Ortiz; Sanford M Simon Journal: Cancer Discov Date: 2021-06-14 Impact factor: 39.397